BDSX — Biodesix, Inc.

Biodesix, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $25.6 million, a 42% increase year-over-year.
• Diagnostic Testing Revenue: $22.3 million, up 37% year-over-year, driven by a 29% increase in test volumes (approximately 17.8 thousand tests).
• Development Services Revenue: Nearly doubled year-over-year to $3.3 million, reflecting successful contracted programs and new agreements.
• Gross Margin: 84% (GAAP), 82% excluding a one-time tax recovery, marking a 300 basis point improvement year-over-year.
• Operating Expenses: $27.6 million, an 18% increase, largely due to sales and marketing expansion.
• Net Loss: $7.8 million, a 30% improvement compared to the prior year.
• Adjusted EBITDA: Loss of $4.1 million, a 35% improvement year-over-year.
• Cash Position: $25.6 million in unrestricted cash, a 35% increase from the previous quarter.

2. Strategic Updates and Business Highlights:

• Focused on three objectives for 2026: driving top-line growth, improving operational efficiency, and advancing the product pipeline.
• Significant progress in the diagnostic testing business, particularly with the Notify Lung test, which is gaining traction among pulmonologists and primary care providers.
• Recent publication of a major clinical validation study for NotifyCDT, enhancing credibility and adoption.
• Continued expansion of the sales force, with plans to add six representatives per quarter throughout 2026.
• Strong interest in development services, supported by multi-omic technologies and advanced data informatics.

3. Forward Guidance and Outlook:

• Revenue Guidance for 2026: Raised to $108 million - $114 million, reflecting a 25% growth over 2025.
• Anticipated continued improvement in sales productivity and operating leverage.
• Expectation of sustained progress towards adjusted EBITDA profitability, driven by increased sales productivity and clinical evidence supporting the Notify Lung test.

4. Bad News, Challenges, or Points of Concern:

• Despite strong growth, the company faces challenges in the broader healthcare landscape, including low compliance rates for lung cancer screening among eligible patients.
• The impact of weather-related disruptions in early Q1, which affected operations and logistics, though the team managed to recover and finish strong.
• Continued reliance on the expansion of the sales force and the need for effective training to ensure productivity gains.

5. Notable Q&A Insights:

• The company is leveraging learnings from primary care channels to enhance sales strategies and improve patient referral processes.
• There is a need for ongoing education for primary care physicians regarding the interpretation of test results and patient management.
• While ASP (average selling price) improvements are expected, future revenue growth is primarily anticipated from increased test volumes rather than significant price increases.
• The development services segment is expected to remain stable, with a focus on volume-driven growth in lung diagnostics.

Overall, Biodesix, Inc. demonstrated strong performance in Q1 2026, with significant revenue growth and operational improvements, while also acknowledging challenges in the healthcare environment and the need for continued focus on sales and education efforts.